Tumor markers in thyroid carcinoma with pulmonary metastases after thyroidectomy

Laboratory Medicine

Volumn 40, Issue 1, 2009, Pages 30-34

  Gao, Yunchao ^a   Lu, Hankui ^a   Yuan, Zhibin ^a   Zhu, Ruisen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; RADIOACTIVE IODINE; THYROGLOBULIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; RADIATION INJURY; SCHOOL CHILD; SENSITIVITY ANALYSIS; SEROLOGY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY;

EID: 77956965935     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LM8FZXW08BRJSJSR     Document Type: Article

References (50)

1. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441. (Pubitemid 36623351)
2. Holt E. Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr Opin Oncol. 2007;19:6-10. (Pubitemid 44885593)
3. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem. 1996;42:164-173. (Pubitemid 26030404)
4. Rosário PW, Maia FF, Fagundes TA, et al. Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: Methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq Bras Endocrinol Metab. 2004;48:487-492.
5. Spencer CA. Editorial: Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab. 2004;89:3702-3704.
6. Persoon AC, Links TP, Wilde J, et al. Thyroglobulin (Tg) recovery testing with quantitative Tg antibody measurement for determining interference in serum Tg assays in differentiated thyroid carcinoma. Clin Chem. 2006;52:1196-1199. (Pubitemid 43794436)
7. Gao Y, Yuan Z, Yu Y, et al. Mutual interference between serum thyroglobulin and antithyroglobulin antibody in an automated chemiluminescent immunoassay. Clin Biochem. 2007;40:735-738.
8. Sánchez R, Espinosa-de-los-Monteros AL, Mendoza V, et al. Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma. Arch Med Res. 2002;33:478-481.
9. Spencer CA, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:5566-5575. (Pubitemid 41415459)
10. Joypaul B, Browning M, Newman E, et al. Comparison of serum CA72-4 and CA19-9 levels in gastric cancer patients and correlation with recurrence. Am J Surg 1995; 169: 595-599.
11. Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian endometrial and cervical cancer. Biomed Pharmacother 2004; 58: 24-38.
12. Duffy MJ, van Dalen A, Haglund C. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003; 39: 718-727.
13. Carpelan-Holmström M, Louhimo J, Stenman UH, et al. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004; 66: 296-302. (Pubitemid 38822799)
14. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA19-9 and CEA in periampullary cancers. J Am College Surg. 1999; 188: 415-420.
15. Louhimo J, Alfthan H, Stenman UH, et al. Serum HCGβ and CA72-4 are stronger prognostic factors than CEA, CA19-9 and CA242 in pancreatic cancer. Oncology 2004; 66: 126-131.
16. Seemann MD, Beinert T, Fürst H, et al. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (Cyfra 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer. 1999; 26: 149-155.
17. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in non-small cell lung cancer: A study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest. 2003;124:622-632. (Pubitemid 37000143)
18. Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol. 2005;203:1-5.
19. Andreadis C, Touloupidis S, Galaktidou G, et al. Serum Cyfra 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol. 2005;174:1771-1776.
20. Tamakoshi K, Kikkawa F, Shibata K, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol. 1996;62:67-72.
21. Schutter EMJ, Davelaar EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of tumor markers (CA125, CA153, and CA72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol. 2002;187:385-392.
22. Tammela J, Lele S. New modalities in detection of recurrent ovarian cancer. Curr Opin Obstet Gynecol. 2004;16:5-9. (Pubitemid 38241536)
23. Tsai CC, Lin H, Huang EY, et al. The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004;94:363-367.
24. Baskić D, Ristić P, Matić S, et al. Clinical evaluation of the simultaneous determination of CA 15-3, CA125 and sHER2 in breast cancer. Biomarkers. 2007;12:657-667. (Pubitemid 350048080)
25. Hashimoto T, Matsubara F, Mizukami Y, et al. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies. Endocrinol Jap. 1990;37:247-254.
26. Carlisle MR, Lu C, McDougall R. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003;24:715-735.
27. Rosário PW, Guimarães VC, Maia FF, et al. Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope. 2005;115:264-267.
28. Kücük ÖN, Gültekin SS, Aras G, et al. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun. 2006;27:261-266.
29. Tenenbaum F, Corone C, Schlumberger M, et al. Thyroglobulin measurement and postablative iodine-131 total body scan after thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer.1996;32A:1262. (Pubitemid 126783095)
30. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2005;90:1440-1445.
31. Mazzaferri EL, Robbins RJ, Braverman LE, et al. Authors' response: A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Meta. 2003;88:4508-4509.
32. Rosário PW, Maia FF, Cardoso LD, et al. Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma. Clin Nucl Med. 2004;29:358-361.
33. Keen CE, Szakacs S, Okon E, et al. CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin. Histopathology. 1999;34:113-117.
34. Kamoshida S, Ogane N, Yasuda M, et al. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas. Mod Pathol. 2000;13:736-741.
35. van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 1998;18:93-97. (Pubitemid 28087009)
36. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342.
37. Giovanella L, Ceriani L, Ghelfo A, et al. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int J Biol Markers. 2008;23:61-64.
38. Ishizaka N, Ishizaka Y, Toda EI, et al. Are serum carcinoembryonic antigen levels associated with carotid atherosclerosis in Japanese men? Arterioscler Thromb Vasc Biol. 2008;28:160-165.
39. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308-312.
40. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003;41:1805-1811.
41. Giannini E, Borro P, Botta F, et al. Cholestasis is the main determinant of abnormal CA19-9 levels in patients with liver cirrhosis. Int J Biol Markers. 2000;15:226-230.
42. Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Gastroenterol Clin Biol. 1994;18:17-20.
43. Tramonti G, Ferdeghini M, Donadio C, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, Cyfra 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect Prev. 2000;24:86-90. (Pubitemid 30152744)
44. Seemann MD, Beinert T, Furst H, et al. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (Cyfra 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer. 1999;26:149-155.
45. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2004;3:464-468. (Pubitemid 39173087)
46. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-408.
47. Kikkawa F, Nawa A, Kajiyama H, et al. Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol. 2006;103:171-175.
48. Mandorwski S, Lourenco LG, Forones NM. CA72-4 and CEA in serum and peritoneal washing in gastric cancer. Arq Gastroenterol. 2002;39:17-21.
49. Ychou M, Duffour J, Kramar A, et al. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16:105-110.
50. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959.